|
WO2002092020A2
(en)
|
2001-03-23 |
2002-11-21 |
The Burnham Institute |
Compositions and methods for modulating bone mineral deposition
|
|
US20030078232A1
(en)
|
2001-08-08 |
2003-04-24 |
Elfatih Elzein |
Adenosine receptor A3 agonists
|
|
JP2005516917A
(ja)
|
2001-12-12 |
2005-06-09 |
アメリカ合衆国 |
細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法
|
|
WO2004079013A1
(en)
|
2003-03-03 |
2004-09-16 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
US20090142347A1
(en)
|
2004-09-29 |
2009-06-04 |
The Burnham Institute For Medical Research |
Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
|
|
JP5238936B2
(ja)
|
2005-03-25 |
2013-07-17 |
ジーアイティーアール,インク. |
Gitr結合分子およびその使用
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
JP2009519236A
(ja)
|
2005-11-30 |
2009-05-14 |
キャン−ファイト・バイオファーマ・リミテッド |
A3アデノシンレセプター抗体の治療的使用
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
PT2175884T
(pt)
|
2007-07-12 |
2016-09-21 |
Gitr Inc |
Terapias de combinação empregando moléculas de ligação a gitr
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
EP3153526B1
(en)
|
2008-01-31 |
2020-09-23 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
IN2015DN02826A
(cg-RX-API-DMAC10.html)
|
2009-09-03 |
2015-09-11 |
Merck Sharp & Dohme |
|
|
DK2510010T3
(en)
|
2009-12-10 |
2015-12-14 |
Hoffmann La Roche |
Antibodies that bind to human CSF1R extracellular domain 4 and their use
|
|
DK2542256T3
(da)
|
2010-03-04 |
2019-08-26 |
Macrogenics Inc |
Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
|
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
RU2617971C2
(ru)
|
2010-03-05 |
2017-04-28 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против csf-1r человека и их применение
|
|
EP3943154A1
(en)
|
2010-05-04 |
2022-01-26 |
Five Prime Therapeutics, Inc. |
Antibodies that bind csf1r
|
|
EP2580243B1
(en)
|
2010-06-09 |
2019-10-16 |
Genmab A/S |
Antibodies against human cd38
|
|
WO2012031008A2
(en)
*
|
2010-08-31 |
2012-03-08 |
The General Hospital Corporation |
Cancer-related biological materials in microvesicles
|
|
WO2012031320A1
(en)
|
2010-09-06 |
2012-03-15 |
Peter Maccallum Cancer Institute |
Cancer diagnostic
|
|
NZ729044A
(en)
|
2010-09-09 |
2020-07-31 |
Pfizer |
4-1bb binding molecules
|
|
WO2012085132A1
(en)
|
2010-12-22 |
2012-06-28 |
Orega Biotech |
Antibodies against human cd39 and use thereof
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
MX356337B
(es)
|
2011-12-15 |
2018-05-23 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
|
MX2014008961A
(es)
|
2012-02-06 |
2014-10-14 |
Genentech Inc |
Composiciones y metodos para utilizar inhibidores de csf1r.
|
|
AU2013222345B2
(en)
|
2012-02-22 |
2017-09-07 |
Sanford-Burnham Medical Research Institute |
Sulfonamide compounds and uses as TNAP inhibitors
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
KR20150018533A
(ko)
|
2012-05-11 |
2015-02-23 |
파이브 프라임 테라퓨틱스, 인크. |
콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
US9307487B2
(en)
|
2013-08-30 |
2016-04-05 |
Qualcomm Incorporated |
Methods and systems for improved utilization of a wireless medium
|
|
EP3134411B1
(en)
|
2014-04-25 |
2021-06-30 |
Boehringer Ingelheim International GmbH |
Purine derivatives as cd73 inhibitors for the treatment of cancer
|
|
RS62003B2
(sr)
*
|
2014-11-10 |
2025-01-31 |
Medimmune Ltd |
Vezujući molekuli specifični za cd73 i njihove upotrebe
|
|
EP3789403A1
(en)
|
2014-11-11 |
2021-03-10 |
MedImmune Limited |
Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
EP3380519A1
(en)
|
2015-11-23 |
2018-10-03 |
Innate Pharma |
Cd39 vascular isoform targeting agents
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
LT3399984T
(lt)
|
2016-01-08 |
2023-11-10 |
Arcus Biosciences, Inc. |
5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas
|
|
AU2017228470A1
(en)
|
2016-03-04 |
2018-08-30 |
Bristol-Myers Squibb Company |
Combination therapy with anti-CD73 antibodies
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
WO2018067424A1
(en)
|
2016-10-03 |
2018-04-12 |
Arcus Biosciences, Inc. |
Inhibitors of adenosine 5'-nucleotidase
|
|
CN110022881B
(zh)
|
2016-11-18 |
2023-05-02 |
艾库斯生物科学有限公司 |
Cd73介导的免疫抑制的抑制剂
|
|
KR102638592B1
(ko)
|
2016-12-22 |
2024-02-19 |
안텐진 테라퓨틱스 리미티드 |
엑토뉴클레오티다제 억제제 및 이의 용도
|
|
ES2985986T3
(es)
|
2017-01-06 |
2024-11-08 |
Bicyclerd Ltd |
Conjugado biciclo para tratar el cáncer
|
|
MX389798B
(es)
|
2017-01-20 |
2025-03-20 |
Arcus Biosciences Inc |
Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer.
|
|
CA3045376C
(en)
|
2017-01-24 |
2022-08-30 |
I-Mab |
Anti-cd73 antibodies and uses thereof
|
|
WO2018183635A1
(en)
|
2017-03-31 |
2018-10-04 |
Peloton Therapeutics, Inc. |
Cd73 inhibitors and uses thereof
|
|
WO2018187512A1
(en)
|
2017-04-04 |
2018-10-11 |
Corvus Pharmaceuticals, Inc. |
Methods for treating cd73hi tumors
|
|
WO2018187484A1
(en)
*
|
2017-04-04 |
2018-10-11 |
Corvus Pharmaceuticals, Inc. |
Methods of treating cancer
|
|
US20190022096A1
(en)
|
2017-04-04 |
2019-01-24 |
Corvus Pharmaceuticals, Inc. |
Methods of treating cancer
|
|
EP3618829B1
(en)
|
2017-05-05 |
2023-06-07 |
Arcus Biosciences, Inc. |
Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
|
|
WO2018208727A1
(en)
|
2017-05-08 |
2018-11-15 |
Eternity Bioscience Inc. |
Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
|
|
US11129841B2
(en)
|
2017-05-10 |
2021-09-28 |
Oric Pharmaceuticals, Inc. |
CD73 inhibitors
|
|
CN110636846B
(zh)
|
2017-05-17 |
2023-05-16 |
艾库斯生物科学有限公司 |
用于治疗癌症相关疾病的喹唑啉吡唑衍生物
|
|
KR102770106B1
(ko)
|
2017-06-08 |
2025-02-21 |
블랙 벨트 테라퓨틱스 리미티드 |
Cd38 조정 항체
|
|
MX2019015885A
(es)
|
2017-06-22 |
2020-09-10 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
|
|
US20200172628A1
(en)
*
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CN107286146B
(zh)
|
2017-07-05 |
2020-07-31 |
上海肇钰医药科技有限公司 |
作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途
|
|
WO2019023635A1
(en)
|
2017-07-27 |
2019-01-31 |
Stingray Therapeutics, Inc. |
SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER
|
|
JP7299873B2
(ja)
|
2017-08-16 |
2023-06-28 |
ブラック ベルト セラピューティクス リミテッド |
Cd38抗体
|
|
AU2018316521B2
(en)
|
2017-08-16 |
2025-01-30 |
Black Belt Therapeutics Limited |
CD38 modulating antibody
|
|
CA3080976A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Corvus Pharmaceuticals, Inc. |
Adenosine pathway inhibitors for cancer treatment
|
|
CA3090922A1
(en)
|
2018-02-16 |
2019-08-22 |
Arcus Biosciences, Inc. |
Dosing with an azolopyrimidine compound
|
|
TWI702954B
(zh)
|
2018-03-01 |
2020-09-01 |
美商美國禮來大藥廠 |
Cd73抑制劑
|
|
WO2019173682A1
(en)
|
2018-03-09 |
2019-09-12 |
Arcus Biosciences, Inc. |
Parenterally administered immune enhancing drugs
|
|
CA3096674A1
(en)
|
2018-04-12 |
2019-10-17 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
|
TW202012637A
(zh)
|
2018-04-24 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
治療癌症之方法
|
|
EP3823614A4
(en)
|
2018-07-18 |
2022-03-30 |
Arcus Biosciences, Inc. |
SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND
|
|
AU2019312296B2
(en)
|
2018-07-27 |
2025-05-29 |
Arcus Biosciences, Inc. |
Pyridone A2R antagonists
|
|
ES3053198T3
(en)
|
2018-08-27 |
2026-01-20 |
Arcus Biosciences Inc |
Cd73 inhibitors
|
|
EP3863664A1
(en)
|
2018-10-11 |
2021-08-18 |
Pfizer Inc. |
Dosage regimen for tfpi antagonists
|
|
EP3893891A4
(en)
|
2018-12-13 |
2022-08-03 |
Arcus Biosciences, Inc. |
SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE
|
|
CA3135487A1
(en)
|
2019-03-29 |
2020-10-08 |
Arcus Biosciences, Inc. |
Treatment of cancer utilizing an identified adenosine fingerprint
|
|
EP4084870A1
(en)
|
2020-01-03 |
2022-11-09 |
Incyte Corporation |
Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
|
|
US11633416B1
(en)
|
2020-03-06 |
2023-04-25 |
Arcus Biosciences, Inc. |
Oral formulations of CD73 compounds
|
|
CA3179320A1
(en)
*
|
2020-06-17 |
2021-12-23 |
Arcus Biosciences, Inc. |
Crystalline forms of a cd73 inhibitor and uses thereof
|